Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression

NCT03052478 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasms

Interventions

DRUG: Vismodegib 150 mg

Sponsor

Samsung Medical Center